Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 ...

93750公斤可售量 中国 固定化葡萄糖异构酶生产厂家 产品区域 固定化葡萄糖异构酶厂家固定化葡萄糖异构酶生产厂家固定化葡萄糖异构酶食品级固定化葡萄糖异构酶价格 固定化葡萄糖异构酶 GENSWEET TM IGI—SA 是一种固定化葡萄糖异构酶【EC.5.3.1.5.,D—木糖酮醇 ...

Previously known as the Model 2, but more recently referred to as the Model Q, a compact Tesla could sit below £30,000, where it would bring top-notch EV tech, including Tesla’s Supercharger ...

The Zymeworks (NASDAQ:ZYME) story over the last two years was one of transformation and execution. The process started with the out-licensing of Ziihera, the brand name for zanidatamab ...

Stock futures edged lower on Tuesday as investors weighed the possibility of the Fed delivering its final rate cut in 2024, with focus shifting to hints about the central bank's outlook for 2025.

Mitek Systems ( (MITK)) has released its Q4 earnings. Here is a breakdown of the information Mitek Systems presented to its investors. Mitek Systems, Inc., a global leader in digital identity ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report), Zymeworks (ZYME – Research Report) and Axsome ...

So, the natural question for Zymeworks (NASDAQ:ZYME) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at ...